A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer

Published on Jun 15, 2020in International Journal of Cancer5.145
· DOI :10.1002/IJC.32822
Carolina Reduzzi6
Estimated H-index: 6
Marta Vismara2
Estimated H-index: 2
+ 6 AuthorsVera Cappelletti21
Estimated H-index: 21
In biliary tract cancer (BTC), tissue biopsies to guide treatment are rarely feasible, thus implementing liquid biopsy approaches to improve patient management represents a priority. So far, studies on circulating tumor cells (CTCs) in BTC are insufficient to promote their use in patient clinical management and are limited to EpCAM-enriched CTCs evaluated with the CellSearch. We applied a single-cell protocol allowing identification not only of epithelial CTCs (eCTCs), but also of nonconventional CTCs (ncCTCs) lacking epithelial and leukocyte markers, but presenting aberrant genomes as confirmed by copy number alterations and therefore representing a distinct subpopulation of bona fide CTCs. In 41 blood samples longitudinally collected from 21 patients with advanced-stage BTC, addition of ncCTC to classic eCTC led to a CTC-positivity increase from 19% to 83%. Patients presenting with at least 1 eCTC/10 ml of blood at baseline prior to treatment start had a significantly shorter median disease-specific survival (DSS) compared to those lacking eCTCs (9 months vs. 19 months, p = 0.03 by log-rank test). No differences in DSS were observed according to ncCTC-positivity, conversely, variations in ncCTC counts during, and at the end of treatment, were associated with the RECIST response supporting their role in treatment monitoring. Moreover, in 88 ncCTCs collected at different times during treatment, unsupervised clustering evidenced segregation of cells by patient's best response, allowing identification of genomic regions possibly involved in resistance mechanisms. The presence of ncCTCs beside eCTCs opens the way to exploiting liquid biopsy for optimizing clinical management in BTC.
📖 Papers frequently viewed together
9 Authors (Cassie J Liu, ..., SP Thayer)
14 Authors (Marco Wendel, ..., Peter Kuhn)
97 Citations
10 Authors (Awe A. Julius, ..., Sabine Mai)
#1Maeve A. Lowery (Trinity College, Dublin)H-Index: 25
#2Ryan Ptashkin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
Last. Ghassan K. Abou-Alfa (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 44
view all 20 authors...
Purpose: Various genetic driver aberrations have been identified among distinct anatomic and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and these molecular alterations may be prognostic biomarkers and/or predictive of drug response. Experimental Design: Tumor samples from patients with cholangiocarcinoma who consented prospectively were analyzed using the MSK-IMPACT platform, a targeted next generation sequencing assay that analyzes all exons and selected introns of 4...
85 CitationsSource
#1Alison BackenH-Index: 17
#2Andre Lopes (UCL: University College London)H-Index: 12
Last. Juan W. Valle (University of Manchester)H-Index: 48
view all 19 authors...
Advanced biliary tract cancer (ABC) has a poor prognosis. Cediranib, in addition to cisplatin/gemcitabine [CisGem], improved the response rate, but did not improve the progression-free survival (PFS) in the ABC-03 study. Minimally invasive biomarkers predictive of cediranib benefit may improve patient outcomes. Changes in 15 circulating plasma angiogenesis or inflammatory-related proteins and cytokeratin-18 (CK18), measured at baseline and during therapy until disease progression, were correlate...
7 CitationsSource
#2Masashi FujitaH-Index: 10
Last. Hidewaki NakagawaH-Index: 12
view all 38 authors...
Background & Aims Biliary tract cancers (BTCs) are clinically and pathologically heterogeneous and respond poorly to treatment. Genomic profiling can offer a clearer understanding of their carcinogenesis, classification and treatment strategy. We performed large-scale genome sequencing analyses on BTCs to investigate their somatic and germline driver events and characterize their genomic landscape. Methods We analyzed 412 BTC samples from Japanese and Italian populations, 107 by whole-exome sequ...
75 CitationsSource
#1Sumera Rizvi (Mayo Clinic)H-Index: 19
#2Shahid A. Khan (Imperial College London)H-Index: 32
Last. Gregory J. Gores (Mayo Clinic)H-Index: 131
view all 5 authors...
Cholangiocarcinoma, the second most common form of liver cancer after hepatocellular carcinoma, is a heterogeneous disease entity with a near-universal poor prognosis. Our understanding of the epidemiology and biology of cholangiocarcinoma is increasing, and importantly, potentially actionable molecular and immunological targets for novel therapies are increasingly being identified. Herein, the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma are revi...
336 CitationsSource
#1Apinya Jusakul (NUS: National University of Singapore)H-Index: 13
#2Ioana Cutcutache (NUS: National University of Singapore)H-Index: 19
Last. Patrick TanH-Index: 74
view all 58 authors...
Cholangiocarcinoma (CCA) is a hepatobiliary malignancy exhibiting high incidence in countries with endemic liver-fluke infection. We analysed 489 CCAs from 10 countries, combining whole-genome (71 cases), targeted/exome, copy-number, gene expression, and DNA methylation information. Integrative clustering defined four CCA clusters - Fluke-Positive CCAs (Clusters 1/2) are enriched in ERBB2 amplifications and TP53 mutations, conversely Fluke-Negative CCAs (Clusters 3/4) exhibit high copy-number al...
239 CitationsSource
#1Vincenzo CardinaleH-Index: 37
#2Eugenio Gaudio (American Board of Legal Medicine)H-Index: 50
Last. Michael D. McLellanH-Index: 64
view all 202 authors...
73 CitationsSource
#1Farshad Farshidfar (U of C: University of Calgary)H-Index: 14
#1Consortia (U of C: University of Calgary)H-Index: 1
Last. Lawrence N. Kwong (University of Texas MD Anderson Cancer Center)H-Index: 27
view all 1 authors...
Summary Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevat...
229 CitationsSource
#1Luc Cabel (PSL Research University)H-Index: 11
#2Charlotte Proudhon (PSL Research University)H-Index: 20
Last. François-Clément Bidard (PSL Research University)H-Index: 42
view all 7 authors...
Circulating tumor cells (CTCs) are rare tumor cells and have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. Although CTCs are not currently used in clinical practice, CTC studies have accumulated a high level of clinical validity, especially in breast, lung, prostate and colorectal cancers. In this review, we present an overview of the current clinical validity of CTCs in metastatic and non-metastatic disease, and the main concepts and studies inve...
83 CitationsSource
#2Sonja Mader (UHH: University of Hamburg)H-Index: 2
Last. Klaus Pantel (UHH: University of Hamburg)H-Index: 106
view all 3 authors...
Epithelial-to-Mesenchymal Transition (EMT) is a complex process that supports the migratory capacity of epithelial tumor cells and is thought to play a crucial role in promoting cancer metastasis. Despite the wealth of experimental data, the exact role of EMT in cancer patients remains more controversial. Over the past 10 years, sensitive technologies that allow the detection and molecular characterization of circulating tumor cells (CTCs) in the peripheral blood of tumor patients have been deve...
70 CitationsSource
Genomic characterization of circulating tumor cells (CTCs) enables the monitoring of tumor progression and of adaption occurring during treatment. CTC molecular characterization represents indeed a precious tool to implement in the clinical practice for better dealing with acquired resistance to systemic treatment and tumor evolution. Unfortunately CTCs are very rare and enrichments from blood samples and subsequent identification of these cells are technically very challenging. We describe here...
6 CitationsSource
Cited By2
#1Marco SilvestriH-Index: 3
#2Carolina ReduzziH-Index: 6
Last. Vera CappellettiH-Index: 21
view all 15 authors...
Circulating tumor microemboli (CTMs) are clusters of cancer cells detached from solid tumors, whose study can reveal mechanisms underlying metastatization. As they frequently comprise unknown fractions of leukocytes, the analysis of copy number alterations (CNAs) is challenging. To address this, we titrated known numbers of leukocytes into cancer cells (MDA-MB-453 and MDA-MB-36, displaying high and low DNA content, respectively) generating tumor fractions from 0–100%. After low-pass sequencing, ...
Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of epithelial markers hindering CTC-enrichment approaches exploiting epithelial cell surface proteins. In 21 blood samples serially collected from 10 patients with metastatic RCC entering the TARIBO trial, we overcame this limitation using the marker-independent Parsortix...
4 CitationsSource